Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1[frac12] diabetes in patients presenting with type 2 diabetes

Metabolism ◽  
2001 ◽  
Vol 50 (9) ◽  
pp. 1008-1013 ◽  
Author(s):  
Rattan Juneja ◽  
Irl B. Hirsch ◽  
Ramachandra G. Naik ◽  
Barbara M. Brooks-Worrell ◽  
Carla J. Greenbaum ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Islet Cell ◽  
Clinical Phenotype ◽  
Islet Cell Antibodies ◽  
Acid Decarboxylase ◽  
Glutamic Acid Decarboxylase Antibodies

scholarly journals Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults

2016 ◽  
Vol 2016 ◽  
Author(s):  
E Rapti ◽  
S Karras ◽  
M Grammatiki ◽  
A Mousiolis ◽  
X Tsekmekidou ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vitamin D ◽  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Autoimmune Diabetes ◽  
Combined Treatment ◽  
Acid Decarboxylase ◽  
Latent Autoimmune Diabetes ◽  
Glutamic Acid Decarboxylase Antibodies

Summary Latent autoimmune diabetes in adults (LADA) is a relatively new type of diabetes with a clinical phenotype of type 2 diabetes (T2D) and an immunological milieu characterized by high titers of islet autoantibodies, resembling the immunological profile of type 1 diabetes (T1D). Herein, we report a case of a young male, diagnosed with LADA based on both clinical presentation and positive anti-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) (sitagliptin) and cholecalciferol. Learning points Anti-glutamic acid decarboxylase antibodies (GAD-abs) titers in young patients being previously diagnosed as type 2 diabetes (T2D) may help establish the diagnosis of latent autoimmune diabetes in adults (LADA). Sitagliptin administration in patients with LADA might prolong the insulin-free period. Vitamin D administration in patients with LADA might have a protective effect on the progression of the disease.

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes

The Lancet ◽  
1997 ◽  
Vol 350 (9087) ◽  
pp. 1288-1293 ◽  
Author(s):  
Robert Turner ◽  
Irene Stratton ◽  
Virginia Horton ◽  
Sue Manley ◽  
Paul Zimmet ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Islet Cell ◽  
Insulin Requirement ◽  
Acid Decarboxylase ◽  
Cell Cytoplasm

Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes

2008 ◽  
Vol 63 (1) ◽  
pp. 127-128 ◽  
Author(s):  
Pasquale Striano ◽  
Giuseppe Perruolo ◽  
Luca Errichiello ◽  
Pietro Formisano ◽  
Francesco Beguinot ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Idiopathic Generalized Epilepsy ◽  
Glutamic Acid Decarboxylase Antibodies ◽  
Generalized Epilepsy

Low agreement between radio binding assays in analyzing glutamic acid decarboxylase (GAD65Ab) autoantibodies in patients classified with type 2 diabetes

Autoimmunity ◽  
2009 ◽  
Vol 42 (6) ◽  
pp. 507-514 ◽  
Author(s):  
Bledar Daka ◽  
Maria K. Svensson ◽  
Åke Lernmark ◽  
Lucia Mincheva-Nilsson ◽  
Göran Hallmans ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Binding Assays
Sign in / Sign up

Export Citation Format

Share Document